Results 81 to 90 of about 126,534 (277)

A Simplified Three‐Tailed N‐Alkyl Phosphoramidate Lipid Platform Enables Inguinal Adipose‐Accumulated mRNA Delivery for Anti‐Obesity Therapy

Advanced Science, EarlyView.
This study develops an mRNA therapy encoding a long‐acting GLP‐1/FGF21 fusion protein. A three‐tailed ionizable lipid engineered three‐component lipid nanoparticle delivers the mRNA to inguinal adipose tissue. In obese mice, this targeted, dual‐hormone treatment potently reduces body weight, fat mass, presenting a localized strategy for metabolic ...
Bin Ma, Yunxuan Liu, Huijuan Zhang, Yian Fang, Yizhe Xue, Junsheng Xue, Ziqiong Jiang, Tianyan Zhou, Yanyun Hao, Fei Xie, Lei Miao   +10 more
wiley   +1 more source

Treatment of type 2 diabetes by free fatty acid receptor agonists [PDF]

, 2014
Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors.
Hudson, Brian D., Milligan, Graeme, Ulven, Trond, Watterson, Kenneth R.   +3 more
core   +2 more sources

Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation

Advanced Science, EarlyView.
This target trial emulation in solid organ transplant candidates with obesity and type 2 diabetes evaluates whether pre‐transplant dual therapy with GLP‐1 receptor agonists plus SGLT2 inhibitors is associated with post‐transplant mortality and kidney graft outcomes compared with monotherapy or usual care, using multinational electronic health records ...
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Yen‐Liang Liu, Gideon Meyerowitz‐Katz, Tsung‐Hsun Tsai, Pen‐Hua Su   +7 more
wiley   +1 more source

Comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? [PDF]

, 2014
Adam M.
A. M. Deane, Deane, Deane, Deane, M. Horowitz, Schwartz, Umpierrez   +6 more
core   +1 more source

Selenoprotein H Functions as a PPARα Coactivator to Link Selenium Homeostasis to Hepatic Lipid Metabolism and Protect against Steatohepatitis

Advanced Science, EarlyView.
Our study identifies selenium deficiency as a hallmark of MASH pathogenesis. Dietary selenium supplementation enhances hepatic fatty acid oxidation (FAO) and attenuates MASH progression by activating the PPARα pathway via selenoprotein H (SELENOH). This selenium‐SELENOH‐PPARα nexus redefines the functional scope of selenoproteins, moving from redox ...
Yuwei Zhang, Yuchen Wang, Binbin Li, Xin Li, Chenyu Liu, Yanhao Chen, Cheng Tian, Dongmei Wang, Xiaosong Gu, Chunping Jiang, Yuda Wei, Qiurong Ding   +11 more
wiley   +1 more source

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

Diabetes, Metabolic Syndrome and Obesity, 2019
Rebecca Howell,1 Adrienne M Wright,1 Jennifer N Clements2 1Presbyterian College School of Pharmacy, Clinton, SC 29325, USA; 2Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, SC 29325, USA Abstract: Metformin is the first-
Howell R, Wright AM, Clements JN
doaj  

Commentary on “Electroacupuncture Inhibited Spinal Glial Activation in Neuropathic Pain via Glucagon-like Peptide 1/Glucagon-like Peptide 1 Receptor Signaling”

Neurological Sciences and Neurophysiology
Neuropathic pain represents a significant clinical challenge due to its complex etiology and limited treatment options. Traditional pharmacological approaches, particularly opioid therapy, are associated with significant side effects and risk of abuse ...
Hulya Karatas
doaj   +1 more source

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study

Journal of Diabetes Investigation, 2022
Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) might be less effective in patients with severe hyperglycemia, because hyperglycemia downregulated the GLP‐1 receptor in an animal study.
Yumie Takeshita, Yuki Kita, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Chisato Teramura, Yasufumi Enyama, Toshinari Takamura, the Establishment of Rationale for Antiaging Diabetic Medicine (ERA‐DM) Study Group   +8 more
doaj   +1 more source

Gut Microbiota‐Non‐Coding RNA Axis in Immune Modulation and Disease: From Mechanisms to Clinical Translation

Advanced Science, EarlyView.
ABSTRACT Immune homeostasis is indispensable for preserving organismal integrity, orchestrated through complex molecular networks encompassing immune cell dynamics, microbial cues, and epigenetic regulation. Among these, the gut microbiota‐non‐coding RNA (ncRNA) axis has recently garnered substantial attention as a multifaceted modulator of host ...
Bonan Chen, Guoming Chen, Xieyuan Leng, Qianfan Li, Wenhao Wu, Wenqiu Wu, Zixuan Liu, Zilan Zhong, Xiaohong Zheng, Wei Kang, Fazheng Ren, Yigan Zhang, Juan Chen   +12 more
wiley   +1 more source

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes [PDF]

, 2018
Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk ...
Considine, Robert V., Goodwill, Adam, Green, Mark A., Hamilton, LaTonya, Hutchins, Gary D., Mather, Kieren J., Mathias, Carla, Patel, Niral A., Territo, Wendy, Tune, Johnathan D.   +9 more
core   +1 more source